FAAH is a cytosolic serine hydrolase responsible for the degradation of fatty acid amides, including AEA. Finding inhibitors to FAAH could offer a beneficial approach toward the treatment of pain, obesity, and various neurological diseases where higher endocannabinoid activity would be beneficial. Cayman's FAAH Inhibitor Screening Assay provides a convenient fluorescence-based method for screening FAAH inhibitors. FAAH hydrolyzes AMC-arachidonoyl amide resulting in the release of the fluorescent product, 7-amino-4-methylcoumarin (AMC). The fluorophore can be easily analyzed using an excitation wavelength between 340-360 nm and an emission wavelength between 450-465 nm.